BEACON EMR HIPAA Disclaimer Site Map Social Media
BayCare Health System
Community Benefit Financial Assistance Policy Quality Report Card Health Library News Doctor Connect Find Us
Services Hospitals Find A Doctor Classes & Events About Us Careers Contact Us Get E-Newsletter
Jak2 V617F Mutation
 Back  Back


May We Help You?
 

Call 1-877-692-2922
Monday-Friday, 8am to 5pm

Persons with hearing and speech disabilities can reach the above number through TDD and other specialized equipment by calling the Florida Relay Service at 711.

Contact Us
Send 
e-mail
Search jobs


Decrease (-) Restore Default Increase (+) Font Size
Print    Email

Jak2 V617F Mutation

Test name:
Jak2 V617F mutation

Order name:
JAK2

Specimen requirements:
EDTA peripheral blood or bone marrow

Minimum volume:
0.5mL.

Storage and stability information:
Room temperature, 1 week

Test performed:
Once per week

Methodology:
Real-time Polymerase Chain Reaction (PCR)

Reference range:
Negative for the Jak2 V617F mutation

Clinical significance:
The mutation affecting the Janus Tyrosine Kinase 2 (JAK2 V617F) is the most common molecular abnormality in chronic Myeloproliferative Disorders (MPD). The highest mutation frequency occurs in patients with PV (Polycythemia Vera, >90%) or ET (Essential Thrombocythemia, 35% to 70%); the lowest frequency is in PMF patients (Primary Myelofibrosis, 50%).

CPT codes:
81270


Serving The Tampa Bay Area © Copyright 2014 BayCare Health System